These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 2879325

  • 1. Flumezapine, an antagonist of central dopamine and serotonin receptors.
    Fuller RW, Mason NR.
    Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):23-34. PubMed ID: 2879325
    [Abstract] [Full Text] [Related]

  • 2. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate.
    Fuller RW, Snoddy HD.
    Res Commun Chem Pathol Pharmacol; 1992 Jul; 77(1):87-93. PubMed ID: 1359615
    [Abstract] [Full Text] [Related]

  • 3. Central serotonin antagonist activity of ketanserin.
    Fuller RW, Snoddy HD.
    Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):151-4. PubMed ID: 6505385
    [Abstract] [Full Text] [Related]

  • 4. Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats. Characterization by the use of antagonists.
    Fuller RW, Snoddy HD.
    Neuropharmacology; 1984 Dec; 23(12A):1389-94. PubMed ID: 6527743
    [Abstract] [Full Text] [Related]

  • 5. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA.
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [Abstract] [Full Text] [Related]

  • 6. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
    Cohen ML, Fuller RW, Kurz KD, Parli CJ, Mason NR, Meyers DB, Smallwood JK, Toomey RE.
    J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
    [Abstract] [Full Text] [Related]

  • 7. The effects of metergoline and other serotonin receptor antagonists on serum corticosterone in rats.
    Fuller RW, Snoddy HD.
    Endocrinology; 1979 Oct; 105(4):923-8. PubMed ID: 477605
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Adaptation of brain 5HT2 receptors after mianserin treatment: receptor sensitivity, not receptor binding, more accurately correlates with behavior.
    Smith RL, Barrett RJ, Sanders-Bush E.
    J Pharmacol Exp Ther; 1990 Aug; 254(2):484-8. PubMed ID: 2166792
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Preclinical studies on LY237733, a potent and selective serotonergic antagonist.
    Foreman MM, Fuller RW, Nelson DL, Calligaro DO, Kurz KD, Misner JW, Garbrecht WL, Parli CJ.
    J Pharmacol Exp Ther; 1992 Jan; 260(1):51-7. PubMed ID: 1731051
    [Abstract] [Full Text] [Related]

  • 14. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M, Noda Y, Ochi Y, Furukawa K, Une T, Kurumiya S, Hino K, Karasawa T.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [Abstract] [Full Text] [Related]

  • 15. Elevation of serum corticosterone in rats by dopamine agonists related in structure to pergolide.
    Fuller RW, Snoddy HD, Mason NR, Clemens JA, Bemis KG.
    Neuroendocrinology; 1983 Jan; 36(4):285-90. PubMed ID: 6866215
    [Abstract] [Full Text] [Related]

  • 16. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S, Chaki S, Kawashima N, Suzuki Y, Ogawa S, Kumagai T, Nakazato A, Nagamine M, Yamaguchi K, Tomisawa K.
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [Abstract] [Full Text] [Related]

  • 17. Antagonism of a peripheral vascular but not an apparently central serotonergic response by xylamidine and BW 501C67.
    Fuller RW, Kurz KD, Mason NR, Cohen ML.
    Eur J Pharmacol; 1986 Jun 05; 125(1):71-7. PubMed ID: 3732393
    [Abstract] [Full Text] [Related]

  • 18. Characterization of 5-hydroxytryptamine receptors in rat stomach fundus.
    Clineschmidt BV, Reiss DR, Pettibone DJ, Robinson JL.
    J Pharmacol Exp Ther; 1985 Dec 05; 235(3):696-708. PubMed ID: 2934542
    [Abstract] [Full Text] [Related]

  • 19. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA, Davis MD, Akunne HC, Cooke LW, Whetzel SZ, MacKenzie RG, Shih YH, van Leeuwen DH, DeMattos SB, Georgic LM.
    J Pharmacol Exp Ther; 1995 Aug 05; 274(2):898-911. PubMed ID: 7636753
    [Abstract] [Full Text] [Related]

  • 20. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
    Bacopoulos NG.
    J Pharmacol Exp Ther; 1981 Dec 05; 219(3):708-14. PubMed ID: 6170752
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.